Teva Announces FDA Approval of Austedo XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of Austedo

New once-daily Austedo XR regimen now approved in 6, 12, and 24 mg tablet strengths Austedo is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD) and chorea associated with Huntington’s...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news